Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Are peptides legal in Vermont?

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Yes. A Vermont resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a prescriber authorized to practice in Vermont, including by telemedicine or store-and-forward means under 18 V.S.A. section 9361, and can obtain a compounded peptide when it is eligible under federal 503A rules and dispensed by a drug outlet licensed by the Vermont Board of Pharmacy. Under 26 V.S.A. section 2061 every drug outlet must hold a Board license in the right classification, and compounding is its own license class; Vermont has no state bulks list, so peptide compounding eligibility follows the FDA framework.

Regulatory: Telehealth allowedRegulatory: Async allowedRegulatory: Compounded GLP-1 limitedVerified: Verified Oct 4, 2026
Compounding rules
Follows the federal 503A framework
Telehealth prescribing
Allowed, asynchronous allowed; a questionnaire alone is not enough
Compounded GLP-1
Limited

Can a Vermont resident get peptides by telehealth?

18 V.S.A. section 9361 lets a Vermont-licensed health care provider prescribe, dispense, or administer drugs after an appropriate examination performed in person, through telemedicine (defined in 8 V.S.A. section 4098a as live interactive audio and video), or by instrumentation and diagnostic equipment that transmits images and medical records electronically, and it holds electronic prescribing to the same standards as a traditional setting. The section also governs services delivered by store-and-forward means: the patient must be told of the right to refuse that format and ask for a real-time or in-person visit, and originating site providers must obtain informed consent. The Board of Medical Practice telemedicine policy (March 2023), which covers physicians and the other professionals the Board licenses, states that a physician-patient relationship may be established by synchronous or asynchronous telemedicine technologies with no prior in-person meeting, so long as the standard of care is met. Separately, 26 V.S.A. section 1354(a)(33) makes an electronic, online, or telephonic evaluation by questionnaire inadequate for the initial evaluation of a patient, with a narrow exception for an adaptive questionnaire used to prescribe medication to end a pregnancy, and the Board policy says evaluation solely by online questionnaire does not meet the standard of care. The prescriber must be licensed in Vermont or hold a Vermont telehealth license or telehealth registration under 26 V.S.A. chapter 56, issued by the Board of Medical Practice for physicians and by the Office of Professional Regulation for the professions it regulates. GLP-1 medicines and the peptides in this database are not controlled substances. This record classifies asynchronous prescribing as allowed because the statute permits examination through transmitted images and records and the Board policy expressly allows asynchronous establishment of the relationship, but a questionnaire alone is not enough. [4] [5] [6] [7] [8]

How does the Vermont pharmacy board treat compounding?

Compounding regulator for Vermont
BoardVermont Board of Pharmacy (Office of Professional Regulation, Vermont Secretary of State)
Eligible substancesFollows the federal 503A framework

The Vermont Board of Pharmacy, administered by the Office of Professional Regulation, licenses pharmacists and drug outlets under 26 V.S.A. chapter 36. Section 2061 requires every drug outlet to register and hold a license in one or more classifications, including retail, compounding, outsourcing, and home infusion, and the Board sets the criteria for each by rule. The Board's administrative rules effective February 1, 2026 settle both points. Rule 10-9 requires a drug outlet physically located outside Vermont but doing business in Vermont to register for the applicable license type; rule 7-4(b) requires a nonresident outlet to submit an inspection report assessing compliance with applicable law and USP standards, done by its home-state board, the national pharmacy boards association, FDA, or another recognized third party within 2 years before application for a compounding or home infusion pharmacy; and rule 6-2 requires a qualifying inspection at each renewal. Rule 10-4 requires a pharmacy that compounds to register as a compounding pharmacy in addition to its retail license and to comply with 21 U.S.C. 353a, USP chapter 795 for non-sterile compounding, USP chapter 797 for sterile compounding, and USP chapter 800 for hazardous drugs, and to compound only on a patient-specific order or in limited quantities based on regularly observed prescribing patterns. Vermont has not adopted its own list of compoundable bulk substances, so a peptide's eligibility follows the federal 503A test (approved drug component, USP or NF monograph, or FDA 503A bulks list). [1] [2] [3] [9] [10] [12]

Can you get compounded GLP-1s in Vermont?

Regulatory: Compounded GLP-1 limited

A pharmacy compounding a GLP-1 for a Vermont patient must hold the appropriate Vermont drug outlet license, including a nonresident license if it ships from out of state. [1] [10] [15]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in Vermont?

Access options

We may earn a commission from these links.

Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.

Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.

Find a provider in Vermont

What you'll actually find in Vermont, and how to check

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [17] [18] [19]

No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [20]

What Vermont has done

PeptideAgent has not found a board or legislative action on peptides in Vermont.

Other states have acted:

  • On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [22] Mississippi law
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [23] [24] Louisiana law

Checking the prescriber

Telehealth prescribing of non-controlled peptides is permitted in Vermont. A prescriber may prescribe without a live visit (asynchronous care) when it meets the standard of care. State law says an online questionnaire alone is not enough. [4] [5] [6] [7] [8] The telehealth rule in full.

Checking the pharmacy

Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the Vermont Board of Pharmacy (Office of Professional Regulation, Vermont Secretary of State); its license search: FDA BeSafeRx: state board of pharmacy license lookups. [21]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [20]

They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [13] [25] [26]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [21] [27] [28]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [19] [28] [29]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [20] [30] [31] [32] [33] [34]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [20]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [21]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [19]
  • Pharmacy: Is this made for me on a prescription written in my name? [29]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [19] [28]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [19]

What is offered for a specific peptide, and what FDA found, is on each peptide page.

Is it legal to buy research peptides in Vermont?

Under 26 V.S.A. chapter 36, drugs may be dispensed to Vermont patients only by licensed pharmacists working in licensed drug outlets, so a seller shipping "research use only" injectable peptides to Vermont consumers is not a licensed outlet. [9] [16]

Peptide-specific notes for Vermont

Peptide-specific notes for Vermont
PeptideNote
SemaglutideAvailable branded by prescription, including from a Vermont-authorized prescriber after an examination by live audio and video or by equipment that transmits images and medical records under 18 V.S.A. 9361; a questionnaire alone is inadequate for a physician's initial evaluation under 26 V.S.A. 1354(a)(33). Compounded semaglutide is limited to the federal patient specific exception since the 503A grace period ended April 22, 2025. [5] [7] [15]

Frequently asked questions

Can I get a GLP-1 prescription in Vermont through telemedicine?

Yes. 18 V.S.A. section 9361 allows a Vermont-licensed provider to prescribe after an appropriate examination done in person, through live audio and video, or with equipment that transmits images and medical records electronically, held to the same standard as an office visit. A provider not otherwise licensed in Vermont may treat Vermont patients by telehealth only with a Vermont telehealth license or telehealth registration under 26 V.S.A. chapter 56. [5] [11]

Does Vermont allow store-and-forward telehealth?

Yes. 18 V.S.A. section 9361 covers services delivered by store-and-forward means. The patient must be told of the right to refuse that format and ask for a real-time or in-person visit instead. The Board of Medical Practice telemedicine policy says a physician-patient relationship may be established by asynchronous technology so long as the standard of care is met. A questionnaire alone is not enough: 26 V.S.A. section 1354(a)(33) treats evaluation by questionnaire as inadequate for the initial evaluation of a patient. Definitions come from 8 V.S.A. section 4098a. [5] [6] [7] [8]

Does a compounding pharmacy need a Vermont license to ship to me?

Yes. 26 V.S.A. section 2061 requires every drug outlet to hold a Vermont Board of Pharmacy license in the correct classification. Under the Board's 2026 rules, an outlet outside Vermont doing business in the state must register for the applicable license type (rule 10-9), a pharmacy that compounds must also register as a compounding pharmacy (rule 10-4), and a nonresident compounding pharmacy must submit an inspection report from the prior 2 years (rule 7-4). Check the Office of Professional Regulation license lookup before ordering. [2] [3] [10]

Can a Vermont pharmacy compound peptides that are not on the FDA bulks list?

Generally no. Vermont has no state bulks list, so the federal 503A test applies: the substance must be a component of an approved drug, have a USP or NF monograph, or be on the FDA 503A bulks list. Peptides in FDA Category 2 cannot be compounded. [12] [13]

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.

  1. [1]Vermont Board of Pharmacy (Office of Professional Regulation)
  2. [2]Vermont Board of Pharmacy: statutes, rules, and resources
  3. [3]Administrative Rules for the Vermont Board of Pharmacy, effective February 1, 2026 (rules 6-2, 7-4, 10-4, 10-9)
  4. [4]Vermont Office of Professional Regulation
  5. [5]18 V.S.A. section 9361, Health care providers delivering health care services through telemedicine or by store-and-forward means
  6. [6]8 V.S.A. section 4098a, Coverage of health care services delivered through telemedicine and by store-and-forward means (definitions)
  7. [7]26 V.S.A. section 1354, Unprofessional conduct (subdivision (a)(33), prescribing in response to electronic communication)
  8. [8]Vermont Board of Medical Practice: Policy on the Appropriate Use of Telemedicine Technologies in the Practice of Medicine (March 1, 2023)
  9. [9]26 V.S.A. chapter 36, Pharmacy
  10. [10]26 V.S.A. section 2061, Registration and licensure of drug outlets

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 4). Are peptides legal in Vermont?. https://peptideagent.ai/legal/vermont
HTML link
<a href="https://peptideagent.ai/legal/vermont">Are peptides legal in Vermont?</a>, PeptideAgent, updated October 4, 2026.